AUG 11, 2026 · JOURNAL ARTICLE
ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L
Clinical Cancer Research
Single-arm Phase 2 study in a small, heavily pretreated population showing no objective responses; negative result limits strength but rigorous conduct and clear null finding warrant reporting.
Reported
Sample size34
Primary endpoint (ORR)0%
Median PFS1.7 months